南财智讯11月14日电，诚达药业公告，公司股票于2025年11月13日至11月14日连续2个交易日收盘价格 涨幅偏离值累计超过30%，根据深圳证券交易所交易规则，属于股票交易异常波动情形。针对该情况， 公司董事会对公司、控股股东及实际控制人进行了核实。经确认，公司前期披露的信息不存在需要更正 或补充之处；近期无公共传媒报道可能对公司股价产生重大影响的未公开信息；目前经营情况正常，内 外部环境未发生重大变化；公司、控股股东及实际控制人不存在应披露而未披露的重大事项，也未在筹 划重大事项；控股股东及实际控制人在股票异常波动期间未买卖公司股票；公司不存在违反公平信息披 露规定的情形。公司董事会确认，目前没有任何应予以披露而未披露的事项，对股票交易价格产生较大 影响的信息亦不存在。 ...

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

Core Viewpoint - The pharmaceutical sector is experiencing active trading, with innovative drugs and biovaccines showing strong performance, indicating a positive outlook for the industry through 2026 [1] Industry Summary - The pharmaceutical sector has seen significant stock price increases, with companies like Chengda Pharmaceutical, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching a 20% limit up, while others like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also hit the limit up [1] - CITIC Securities forecasts that the investment trend in the pharmaceutical industry will continue to be driven by the concentration of innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices, leading to a stable domestic market environment [1] - The industry is expected to return to a market pricing system based on clinical value and demand, which will contribute to a stable and continuous growth trend in the performance of listed companies [1] Investment Strategy - The pharmaceutical industry is recommended for continued overweight positioning, with suggested investment themes for 2026 including: 1. Innovation-driven and internationalization, focusing on companies that are innovating and expanding internationally in a favorable domestic policy environment [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports due to geopolitical risks [1] 3. New policies and new opportunities, targeting companies benefiting from optimized procurement, medical insurance payment reforms, consumption stimulus policies, and state-owned enterprise reforms [1]

盘面上，福建板块逆势大涨，海峡环保、龙洲股份、平潭发展、中富通（维权）、日上集团、华映科 技、三木集团涨停；医药概念延续涨势，金迪克、康芝药业、海辰药业、众生药业、嘉应只要、特一药 业、诚达药业、人民同泰等涨停；消费股持续活跃，东百集团、真爱美家、三夫户外（维权）、九牧王 涨停；地产板块异动拉升，华夏幸福、盈信发展、荣盛发展等涨停；燃气板块震荡上扬，胜利股份、长 春燃气、国新能源、首华燃气涨停；下跌方面，存储芯片陷入调整。 11月14日，A股市场三大指数集体收跌，截至收盘，沪指报3990.49点，跌0.97%；深证成指报13216.03 点，跌1.93%；创业板指报3111.51点，跌2.82%。总体来看，个股跌多涨少，下跌个股超3300只。沪深 两市全天成交额1.96万亿元，较上个交易日缩量838亿元。 沪指再创反弹新高，3分钟便捷开户，把握投资先机！长江证券三大尊享福利>> ...

Market Overview - The medical services sector increased by 2.17% on November 13, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Top Gainers in Medical Services - Chengda Pharmaceutical (301201) closed at 41.00, up 14.21% with a trading volume of 168,000 shares and a transaction value of 650 million [1] - Digital Human (920670) closed at 18.16, up 5.70% with a trading volume of 114,000 shares [1] - Mucai Pharmaceutical (600721) closed at 9.59, up 4.92% with a trading volume of 338,800 shares [1] - Other notable gainers include ST Zhongzhu (600568) and Haoyuan Pharmaceutical (688131) with increases of 4.81% and 4.59% respectively [1] Market Capital Flow - The medical services sector saw a net inflow of 454 million from institutional investors, while retail investors experienced a net outflow of approximately 20.9 million [2] - The overall trend indicates a strong interest from institutional investors despite the outflow from retail investors [2] Individual Stock Performance - WuXi AppTec (603259) had a significant net inflow of 590 million, representing 11.01% of its trading volume, while it faced a net outflow of 361 million from speculative funds [3] - Other companies like Kanglong Chemical (300759) and Baihua Pharmaceutical (600721) also showed mixed capital flows, with institutional inflows but outflows from speculative and retail investors [3]

证券日报网讯11月12日晚间，诚达药业（301201）发布公告称，公司于2025年11月12日召开职工代表大 会，经与会职工代表推举并表决，陈维汉先生当选公司第六届董事会职工代表董事。 ...

证券日报网讯11月12日晚间，诚达药业（301201）发布公告称，公司于2025年11月12日完成董事会换届 选举，选举葛建利女士为董事长。 ...

每经头条（nbdtoutiao）——谁在替王家卫写《繁花》？揭秘影视剧本层层转包"枪手链" （记者 曾健辉） 2024年1至12月份，诚达药业的营业收入构成为：医药制造业占比55.67%，食品制造业占比43.0%，其 他业务占比0.69%，贸易类收入占比0.65%。 截至发稿，诚达药业市值为56亿元。 每经AI快讯，诚达药业（SZ 301201，收盘价：35.9元）11月12日晚间发布公告称，公司第六届第一次 董事会临时会议于2025年11月12日在公司会议室以现场结合通讯的方式召开。会议审议了《关于聘任高 级管理人员的议案》等文件。 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-046 1、非独立董事：葛建利女士（董事长）、卢刚先生、黄洪林先生、卢瑾女 士、李文绢女士； 2、独立董事：胡永洲先生、姜林先生、周钧明先生； 3、职工代表董事：陈维汉先生。 诚达药业股份有限公司 关于完成董事会换届选举及聘任高级管理人员、证券事务代 表的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日召开 2025 年第二次临时股东大会及职工代表大会，会议审议通过了董事会换届选举等相关 议案，选举产生了公司第六届董事会成员（含职工代表董事）。同日，公司召开 了第六届董事会第一次会议，会议分别审议通过了选举公司董事长、专门委员会 委员，聘任公司高级管理人员、证券事务代表等相关议案。现将具体情况公告如 下： 一、第六届董事会组成情况 公司第六届董事会由以上 9 名董事组成，任期自 2025 年第二次临时股东大 会审议通过之日起至第六届董事会任期届满之日止。 上述人员任职资格均符合相关法律法规及《公司章程》的有关规定，不 ...

根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律法规、规范性文件及《公司章程》的有关规定，公司董事会由 9 名董事组成， 其中设一名职工代表董事。为保障公司董事会构成符合法律法规及《公司章程》 的规定，公司于 2025 年 11 月 12 日召开职工代表大会，经与会职工代表推举并 表决，陈维汉先生当选公司第六届董事会职工代表董事，任期自本次职工代表大 会审议通过之日起至第六届董事会任期届满之日止，陈维汉先生的简历详见附件。 本次选举产生的职工代表董事将与公司 2025 年第二次临时股东大会选举产 生的 8 名董事共同组成公司第六届董事会，公司第六届董事会中兼任公司高级管 理人员和担任职工代表董事的董事人数合计未超过公司董事总数的二分之一，符 合相关法律法规的要求。 特此公告。 诚达药业股份有限公司董事会 证券代码：301201 证券简称：诚达药业 公告编号：2025-047 诚达药业股份有限公司 关于选举第六届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误 ...